Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

(RTTNews) - 2024 has been a banner year for Verona Pharma (VRNA), with its share price surging more than threefold in just 7.5 months. The ...

Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the ...

End-stage COPD is the most severe stage of chronic obstructive pulmonary disease. During this stage, symptoms worsen, and a flare could become life threatening. Chronic obstructive pulmonary ...

Chronic obstructive pulmonary disease (COPD) increases the chances of surgical complications, such as infections and respiratory crises. In fact, long-term survival rates for people with severe COPD ...

Both dupilumab and ensifentrine, a phosphodiesterase (PDE) 3 and PDE4 inhibitor also recently approved for maintenance treatment of COPD, have been shown in clinical trials to reduce exacerbations ...

COPD Important New FDA Approvals for COPD The recommended dosage for adult patients is 300 mg, given every other week. The FDA approved ensifentrine (Ohtuvayre; Verona) for COPD in June. It is a ...